Plain-English translation of NCT07558863 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Type 2 Diabetes research guide โPhase 4 โ The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether two medications called semaglutide and polyethylene glycol loxenatide can help people with type 2 diabetes who have nerve damage affecting their heart. These medications are already used to help control blood sugar, but researchers want to see if they can also repair or prevent the heart nerve damage that sometimes occurs in diabetes. The study will compare people who receive the medication along with standard diabetes care against those who receive standard care alone.
Heart nerve damage in diabetes can cause serious problems like irregular heartbeats, dangerously low blood pressure, and in severe cases, heart attacks. While this medication is known to help control blood sugar, doctors want to understand if it can also protect or heal the heart nerves, which would be an important additional benefit.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you join this study, you'll be randomly placed into one of two groups for 6 months. One group continues standard diabetes care only, while the other receives standard care plus a once-weekly injection of the medication under the skin. Before and after the 6-month period, you'll have blood tests and non-invasive heart tests (including 24-hour heart rate monitoring) to measure how well your heart nerves are working and how the medication affects your blood sugar, weight, and insulin resistance.
AI-generated summary from trial data ยท Jun 13, 2026 ยท Not medical advice
China